Table 3.
Multivariable analysis of factors associated with treatment of 9,993 AYAs 15 to 24 years old by an adult versus pediatric oncology provider.
| Excluding stage | Excluding diagnosis | |||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Age | 1.93 (1.86–2.00) | <0.01 | 1.88 (1.80–1.95) | <0.01 |
| Sex | ||||
| Male | Referent | Referent | ||
| Female | 1.18 (1.02–1.36) | 0.03 | 1.08 (0.92–1.27) | 0.34 |
| Race | ||||
| White | Referent | Referent | ||
| Non-White | 0.80 (0.69–0.94) | <0.01 | 0.77 (0.65–0.91) | <0.01 |
| Socioeconomic status | ||||
| 1 (lowest) | Referent | Referent | ||
| 2 | 0.98 (0.80–1.22) | 0.87 | 1.03 (0.81–1.31) | 0.83 |
| 3 | 1.19 (0.95–1.48) | 0.13 | 1.20 (0.93–1.54) | 0.16 |
| 4 | 1.10 (0.87–1.38) | 0.44 | 1.12 (0.87–1.45) | 0.38 |
| 5 (highest) | 1.05 (0.83–1.32) | 0.70 | 1.13 (0.87–1.47) | 0.35 |
| Diagnosis | ||||
| Lymphoma | Referent | — | — | |
| Leukemia | 0.48 (0.39–0.59) | <0.01 | ||
| Extracranial GCT | 2.26 (1.72–2.98) | <0.01 | ||
| Sarcoma | 0.74 (0.60–0.92) | <0.01 | ||
| CNS malignancy | 0.76 (0.60–0.96) | 0.02 | ||
| Othera | 1.79 (1.41–2.27) | <0.01 | ||
| Stage | ||||
| Metastatic | — | — | Referent | |
| Nonmetastatic | 1.93 (1.62–2.31) | <0.01 | ||
| Unknown | 2.80 (1.70–4.62) | <0.01 | ||
aIncludes all carcinomas.